

EMORD & ASSOCIATES, P.C.

1050 SEVENTEENTH STREET, N.W.

SUITE 600

WASHINGTON, D.C. 20036

TELEPHONE: (202) 466-6937

TELECOPIER: (202) 466-6938

January 26, 1999

3712 99 JAN 26 P 3:03

VIA HAND DELIVERY
AND TELECOPIER (301) 443-0232

Nicholas P. Reuter
Office of Health Affairs HFY-20
Food and Drug Administration
Rockville, Maryland 20857


Dear Mr. Reuter:

Weider Nutrition International, Inc. ("Weider"), by counsel, hereby requests that the FDA hold a public meeting concerning the World Health Organization's ("WHO's") proposal to limit the international manufacture and distribution of certain substances. This request is in response to the Notice published by the FDA on January 11, 1999. In that notice the agency requested that interested parties submit a request for a public meeting concerning WHO's recommendation to impose international manufacturing and distribution restrictions under international treaties on the substances dihydroetorphine, ephedrine and remifentamil.

Weider Nutrition International, Inc. manufactures and markets dietary supplement products, including some that contain ephedrine alkaloids. As an interested party Weider requests that the FDA hold the public meeting to discuss WHO's proposal; to determine the United States' obligation under the regulations if imposed; to determine whether it will affect domestic distribution of ephedrine products; to gain an understanding of the exact international limitations WHO proposes to impose; and to obtain information on the United States' position on the proposal.

The public meeting is essential to the communication of accurate information concerning the proposal to members of the dietary supplement industry. We look forward to the publication of the place, date and time of the public meeting in the Federal Register.

Sincerely,


Jonathan W. Emord
Claudia A. Lewis-Eng

Counsel for Weider Nutrition International, Inc.

98N-0148

APE3